Skip to main content
SpringerLink
Log in

Progredient-fibrosierende interstitielle Lungenerkrankungen

Nintedanib bremst Krankheitsprogression über ILD-Subgruppen hinweg

  • Journalclub
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Richeldi L, du Bois RM, Raghu G et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med: 2014;370:2071-82

  2. Distler O, Highland KB, Gahlemann M et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380:2518-28

  3. Flaherty KR, Wells AU, Cottin V et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381:1718-27

  4. Wells AU, Flaherty KR, Brown KK et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453-60

  5. Valenzuela C, Maher TM, Bonella F. Effectis of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial. Oral presentation at the European Respiratory Society International Congress 2020. Eposter available at: https://www.globalmedcomms.com/respiratory/ERS2020/Valenzuela

  6. Troy LK, Grainge C, Corte TJ et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020;8:171-81

  7. Raghu G, Anstrom KJ, King TE. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med. 2012;366:1968-77

Download references

Author information

Authors and Affiliations

  1. Zentrum für Pneumologie und Thoraxchirurgie, Asklepios Fachkliniken München-Gauting, Robert-Koch-Allee 2, 82131, Gauting, Germany

    Wolfgang Gesierich

Authors
  1. Wolfgang Gesierich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Gesierich.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gesierich, W. Nintedanib bremst Krankheitsprogression über ILD-Subgruppen hinweg. Pneumo News 13, 16–19 (2021). https://doi.org/10.1007/s15033-021-2759-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-021-2759-z

Search

Navigation